NKMAX Obtains U.S. Patent Related to Natural Killer Cells
[Asia Economy Reporter Kum Boryeong] NKMAX announced on the 29th that it has acquired a U.S. patent related to the "Method for Producing Natural Killer Cells and Anticancer Composition."
Hot Picks Today
While Samsung Falters, China Rises: "Chinese DRAM" Turns a Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
NKMAX stated, "Through this invention, we have secured an immune cell therapeutic substance that can be mass-produced in vitro by thousands of times while maintaining high purity and strong cytotoxicity against cancer cells, even after long-term culture of natural killer cells isolated from peripheral blood." They added, "This substance is planned to be developed into autologous immune cell therapy, allogenic immune cell therapy, and CAR-NK therapy."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
